40 likes | 132 Views
Supplementary Figure 1. A. P-4E-BP1/4E-BP1. P-p70 S6K/p70 S6K. P- Akt / Akt. Relative levels. ND. B. C. c leaved PARP/PARP. LC3II/LC3I. Relative levels. Relative levels. Supplementary Figure 2. Jurkat. SNT13. KHYG1. KAI3. A. *. *. *. *. *. Cell number (x10 5 ). *. *. *.
E N D
Supplementary Figure 1 A P-4E-BP1/4E-BP1 P-p70 S6K/p70 S6K P-Akt/Akt Relative levels ND B C cleaved PARP/PARP LC3II/LC3I Relative levels Relative levels
Supplementary Figure 2 Jurkat SNT13 KHYG1 KAI3 A * * * * * Cell number (x105) * * * * * * * hours hours hours hours B C * * * * * * * * * Viability (% of control) * * MTS reduction (% of control) * Days Rapamycin (nM)
Supplementary Figure 3 B SNT16 - + SNK6 - + A CCI-779 P-4E-BP1 P-p70S6K p27 CDK2 Rb β-Actin C * * * * %of total %of total * * * *
Supplementary Figure 4 * * * * * * Tumor volume (mm3) * CCI-779 * * * * * * Days